Quest Diagnostics DGX
Healthcare · Medical - Diagnostics & Research · Synthos Deep Dive · 2026-07-03
The Overview
Quest Diagnostics runs the blood tests and lab work your doctor orders — it's one of the two giant US lab companies (the other is Labcorp). One in three American adults uses it every year. It's a steady, boring, defensive business: people need lab tests in good times and bad, so revenue is predictable.
The problem isn't the business — it's the price. The stock trades near its all-time high at about 24 times its yearly earnings, which is a full price for a company that only grows earnings around 10-11% a year. You're not getting a bargain, and you're not getting fast growth either. So our verdict is Watch: a fine company to keep an eye on and maybe buy on a pullback, but not a compelling buy today.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (below average risk). The stock is calm and the business is recession-resistant, but the company carries a fair amount of debt and the price leaves little room for a stumble.
- Growth Quality 5/10 (middle of the road). Solid and steady, but a lot of the growth comes from buying other labs rather than growing on its own, and profit margins are ordinary.
- Exponential Potential 2/10 (low). This is a mature utility-like business. Don't expect it to double quickly — it grows a little faster than the economy and pays you a modest dividend.
The one big worry: the government and insurers keep pushing to pay less for lab tests (a rule called PAMA), which squeezes prices — and Quest has borrowed money to buy growth, so a pricing squeeze plus the debt is the thing to watch.
Important honesty note: no outside expert in the Synthos knowledge base covers this stock. This writeup is built purely from the financial data and management's own words, so treat the conviction as lower than a name where independent experts weigh in.
Putting a number on it: our fair-value estimate is $220 against a current price of $242.76 — a premium price for a business we still like.
Our summary metrics
Low beta 0.59 & defensive demand, but 3.1× net-debt/EBITDA and 24× trailing on ~11% growth leave little cushion.
Steady high-single-digit revenue & ~11% EPS CAGR, but 33% gross margin and mid-single ROIC (8%) — acquisition-fueled, not organic-elite.
A mature, defensive lab-testing utility — growth is decelerating toward GDP-plus; no realistic multibagger from a $24B compounder.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature, defensive lab-testing utility — growth is decelerating toward GDP-plus; no realistic multibagger from a $24B compounder.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $220.57 (high $235 / low $210; 13 Buy · 18 Hold · 3 Sell → Hold) — context, not our anchor |
| Valuation | 24× trailing EPS · 20× FY26E · 18× FY27E · 15× FY30E · EV/S 2.7× · EV/EBITDA 14.4× |
| Technicals | Uptrend — $215.72, near 52-wk high, above 50/200-DMA, RSI 67, +20% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices, 0 traceable claims in the Synthos KB; fundamentals/quant driven |
| Position sizing | If owned at all, a small ~1–2% defensive/income sleeve position — not a flagship holding |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for DGX — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $242.76, 9% above the 50-day average ($224), 22% above the 200-day average ($200) — an uptrend. 1% below the 52-week high of $245, 40% above the 52-week low of $173.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $242.76 is currently inside the band (band $231–$247).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 67.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.46, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = DGX · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Quest Diagnostics (NYSE: DGX), founded 1967 and headquartered in Secaucus, NJ, is one of the two dominant US clinical diagnostic information services providers — the lab that processes blood, urine, tissue and molecular tests ordered by clinicians, hospitals, health plans and, increasingly, consumers directly. It serves roughly half of US physicians and hospitals and about one in three adult Americans each year, with ~55,000–57,000 employees and a national network of labs, patient service centers and phlebotomists. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
- By segment: essentially a single reportable segment — Diagnostic Information Services (DIS) $10.79B (~98% of the $11.04B total), with a small products/other remainder. Historically Quest broke this into routine clinical testing, gene-based/esoteric testing, and anatomic pathology; today it reports the consolidated DIS line. The mix has shifted decisively toward Advanced Diagnostics (higher-value esoteric tests: Alzheimer's blood tests, cardiometabolic/endocrine, molecular/MRD oncology).
- By geography: the company does not provide FMP geographic segmentation — the business is overwhelmingly US-domestic, which limits FX risk but concentrates exposure to US reimbursement policy (§11).
The strategic story is threefold: (a) volume growth via hospital/health-system outreach deals (Co-Lab Solutions, e.g. the Corewell Health JV) and consumer testing (questhealth.com); (b) mix shift to Advanced Diagnostics (Alzheimer's AD-Detect, Haystack MRD cancer monitoring); and (c) M&A roll-up of regional and hospital labs — the primary reason revenue jumped double-digits in FY25.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of DGX in the Synthos knowledge base. total_claims = 0; there are zero net-bullish voices and zero cautionary voices distilled for this name. Unlike a conviction-track name, there is no traceable claim_id to cite here, and we will not manufacture one — fabricating conviction is structurally against the house standard.
What this means for the verdict: the entire call below is fundamentals- and quant-driven, cross-checked against management's own (self-interested, half-weighted) guidance in §9. Readers should weight this note accordingly: it is an honest read of the financials, not a synthesis of independent expert opinion. Where a name like this earns only a Watch, the absence of an expert edge is itself part of the reason — Synthos has no differentiated informational advantage on DGX, and the Street already rates it a Hold.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average | Beta 0.59 and genuinely defensive demand cut risk, but net-debt/EBITDA 3.1× (elevated for the sector) and 24× trailing on ~11% growth leave a thin cushion; PAMA reimbursement is a structural overhang. |
| Growth Quality | 5 · Average | Steady high-single-digit revenue and ~11% EPS CAGR, but 33% gross margin, ROIC ~8% and ROE 14% are ordinary, and much of the growth is acquisition-funded (goodwill+intangibles are 65% of assets), not organic-elite. |
| Exponential Potential | 2 · Low | A mature, defensive lab-testing utility. Growth is decelerating toward GDP-plus; at $24B with a US-lab TAM that is large but slow-growing and share already dominant, there is no realistic multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Advanced Diagnostics mix + Alzheimer's/MRD volumes accelerate; accretive M&A continues; margins tick up. FY27E EPS beats to ~$12.5 (vs $11.67 cons); market pays a premium ~21×. | ~$265 (+23%) |
| Base (our anchor) | Guidance roughly holds — FY26 adj EPS ~$10.7, FY27E EPS $11.67; a steady defensive compounder earns ~19×. | ~$220 (+2%) |
| Bear | PAMA/reimbursement cuts bite, M&A integration slips, or utilization normalizes lower. FY27E EPS misses to ~$10.5; multiple de-rates to a defensive-but-levered ~16×. | ~$165 (−24%) |
Synthos fair value = the base case, ~$220 (+2%), with the full $165–$265 span as the honest range. This anchor sits essentially on top of the Street's $220.57 consensus — we see no analytical edge that justifies deviating, which is itself the tell that DGX is fairly-to-fully priced. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). DGX is neither an exponential nor an elite compounder — it is a defensive, mid-quality, mature roll-up:
- Forward growth (estimate): revenue CAGR FY25→FY28E ~5.4% ($11.04B → ~$12.93B); EPS CAGR FY25→FY30E ~11.1% ($8.75 → $14.82 consensus), with the EPS-over-revenue gap coming from buybacks, mix and modest margin lift rather than volume.
- Acceleration (the 2nd derivative) is flat-to-negative: FY25 revenue +11.8% was M&A-boosted; organic is ~5–6% (management cited ~9% organic in Q1'26 on strong volumes, but the multi-year estimate path decelerates — FY26E rev +7%, and the FY29–30 consensus revenue line actually dips, a noisy artifact of thin analyst counts and prior-COVID comparisons). This is a business that grinds a few points above GDP, not one that inflects.
- Room to run: the US lab-testing TAM is large but slow-growing and highly penetrated, and Quest already shares a near-duopoly with Labcorp. At $24B market cap the constraint is not the balance sheet — it is that the addressable growth simply isn't there. A 3–5× from here is not a credible outcome.
- Reinvestment runway: capex is modest (~$527M FY25, ~$550M guided FY26) and the real "reinvestment" is acquisitions — a fine capital-allocation model for a cash cow, but it consumes debt capacity and adds integration risk rather than compounding organically.
Exponential Potential: Low (2/10). Own DGX, if at all, for defensive ballast and a modest dividend, never for a fast multibagger. This honest framing is exactly why DGX does not belong in a flagship "next-exponential" sleeve.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $11.04B, +11.8% (FY24 $9.87B, +6.7% on FY23 $9.25B). The FY25 jump is largely acquisition-assisted (e.g. LifeLabs and other deals); organic is high-single-digit.
- Quarterly trajectory: Q1'25 $2.652B → Q2 $2.761B → Q3 $2.816B → Q4 $2.806B → Q1'26 $2.895B (+9.2% YoY, ~9% organic per management). Steady, seasonally-normal, no inflection.
- Margins: gross 33.2% TTM, EBITDA 18.8%, operating 14.3%, net 9.1% TTM. These are ordinary margins — a labor- and logistics-intensive services business, not a high-margin franchise.
- Earnings: net income $992M FY25 (diluted EPS $8.75) vs $866M / $7.69 FY24. Q1'26 net income $252M, diluted EPS $2.24 reported / $2.50 adjusted.
- Cash flow: operating CF $1.89B FY25, capex −$527M, FCF ~$1.36B (FCF yield ~5.6%). Reliable and dividend-covering; FY26 guided op-CF ~$1.75B.
- Balance sheet: total debt $6.92B, net debt $6.50B, net-debt/EBITDA ~3.1× — elevated, the direct consequence of the M&A model. Goodwill + intangibles are $10.6B (65% of assets); tangible book value is negative. Interest coverage ~6× is adequate but not comfortable. Dividend $3.26/yr (yield 1.5%, ~35% payout), plus modest buybacks (−$450M FY25).
The tell: this is a cash-generative, investment-grade compounder whose growth is bought as much as earned — durable, but leverage and mix, not organic magic.
6. Valuation — priced in or room?
DGX is fairly-to-fully priced, not cheap. At $215.72 it trades 24× trailing EPS ($8.75), and on live consensus the forward multiple is 20× (FY26E $10.75) → 18× (FY27E $11.67) → 15× (FY30E $14.82). EV/EBITDA is 14.4× and EV/sales 2.7× — reasonable for a defensive cash-flow business but not a discount. The PEG (~1.6 trailing) says you're paying a slight premium to the growth rate. A defensive lab utility growing EPS ~11% arguably deserves ~18–20× — which is roughly where it trades, and roughly where the Street's $220.57 target sits. Street targets (context): consensus $220.57, high $235, low $210 — an unusually tight band that reinforces the "fairly valued, low-dispersion" read; the grade split (13 Buy / 18 Hold / 3 Sell) nets to Hold. Our $220 base FV lands on consensus because there is no visible mispricing to exploit. Not a value buy; not a growth buy — a hold-and-watch at this price.
7. Technicals (from the tech block)
- Trend: up. $215.72 sits above the 50-DMA ($197) and 200-DMA ($191), and the 50 is above the 200 (golden-cross posture). MACD +4.7 (positive).
- Location: essentially at the 52-week high (~$216–217), +29.6% off the 52-week low ($166) — a defensive leader making new highs, with a shallow max drawdown (−0.1% from peak in the window).
- Momentum: RSI(14) 67 — strong and approaching overbought (<70), so entering here is buying strength near a stretched reading; a pullback would be a lower-risk entry.
- Relative strength: DGX +20.3% 12-mo vs SPY +20.6% (roughly in line) and vs QQQ +30.3% (lagging the growth index) — but note it outperformed on a 6-mo basis (+22.9% vs SPY +8.4%), classic defensive rotation. It has trailed the Nasdaq's risk-on leadership, as a low-beta name should.
- Read: technicals confirm a healthy defensive uptrend but flag a near-overbought entry at the highs. No technical urgency to buy today; a dip toward the rising 50-DMA (~$197) would improve the risk/reward.
8. Moat & competitive position
Quest's moat is scale and network density in a US duopoly with Labcorp: national logistics (specimen transport), the largest test menu, entrenched relationships with half of US physicians/hospitals, and payer contracts that are hard for sub-scale labs to match. Switching costs for health-system outreach deals are real. But it is a moat of the durable-utility kind, not the pricing-power kind — reimbursement is set largely by CMS and payers, so the moat protects volume and share, not price. The competitive frame: a duopoly with Labcorp (LH), plus hospital in-house labs, and emerging threats from consumer/at-home testing and molecular-diagnostics specialists.
Peer set (FMP-supplied, market cap): Labcorp (LH) $23.5B — the direct comp, Illumina (ILMN) $28.5B, ICON (ICLR) $13.3B, Medpace (MEDP) $15.9B, Incyte (INCY) $23.3B, Waters (WAT) $24.7B, West Pharma (WST) $25.8B, United Therapeutics (UTHR) $23.6B, Tenet (THC) $17.5B, Zimmer Biomet (ZBH) $16.9B. Note the peer list mixes CROs, tools and pharma — the only true operational comp is Labcorp, against which Quest trades at a similar scale and a comparable defensive-growth profile.
9. Management, capital allocation & guidance
- Capital allocation: a disciplined cash cow + M&A roll-up — modest capex (~$550M/yr guided), steady dividend (1.5% yield, ~35% payout), opportunistic buybacks (−$450M FY25), and acquisitions as the primary growth engine, funded partly with debt (hence 3.1× leverage). Appropriate for the business, but it caps ROIC (~8%) and adds integration risk.
- Insider activity: a mix of routine director stock/phantom-unit awards and some officer sales — most notably CEO Jim Davis sold 10,000 shares at $194.14 on 2026-06-01, and an SVP exercised options and sold in early June. These read as routine, likely-scheduled diversification near the highs, not a red-flag cluster, but the CEO sale is worth noting given the stock's rich level.
- Management's own guidance (the earnings-call track — half-weighted; they talk their book): the Q1'26 release (SEC 8-K, filed 2026-04-21) is a genuine earnings release and management raised full-year 2026 guidance: net revenues $11.78–11.90B (+6.8–7.8%), reported diluted EPS $9.58–9.78, adjusted diluted EPS $10.63–10.83, operating cash flow ~$1.75B, capex ~$550M. Management cited "more than 9% revenue growth, almost entirely organic, and ~13% adjusted diluted EPS growth," double-digit Advanced Diagnostics growth (AD-Detect Alzheimer's, Haystack MRD via a new City of Hope collaboration), and an AI Companion patient tool. Half-weight caveat: this is management's self-interested framing; the adjusted EPS excludes amortization and integration charges that are recurring features of the roll-up model — the ~$1/share gap between reported ($9.58–9.78) and adjusted ($10.63–10.83) EPS is material and worth scrutinizing.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $2.81, revenue ~$2.98B). Watch organic volume growth vs revenue-per-requisition (the −1.3% revenue/requisition in Q1'26 shows mix/pricing pressure offset by +10.8% organic volume) and any guidance update.
- Reimbursement / PAMA: any CMS lab fee-schedule cuts or SALSA-reform outcome — the single biggest structural swing factor.
- Advanced Diagnostics ramp: AD-Detect Alzheimer's blood tests and Haystack MRD oncology adoption — the mix-shift-to-higher-margin story.
- M&A cadence & integration: further hospital/regional lab deals and whether leverage stays near ~3× (deleveraging vs re-levering for deals).
- Project Nova: the multi-year order-to-cash system overhaul (first wave fall 2027) — execution/cost risk.
Thesis tripwires (what would change the call): a PAMA/reimbursement cut large enough to compress margins; organic volume growth decelerating below ~4% for two quarters; net-debt/EBITDA rising above ~3.5× on a debt-funded deal; or the reported-vs-adjusted EPS gap widening (integration charges not rolling off).
11. Key risks
- Reimbursement / pricing pressure (structural): CMS PAMA and payer/PBM dynamics cap price; revenue-per-requisition was −1.3% in Q1'26. Lab pricing is a persistent secular headwind.
- Leverage on a roll-up: 3.1× net-debt/EBITDA with negative tangible book value and 65%-of-assets goodwill/intangibles — a pricing squeeze plus rising rates would pressure both earnings and deal capacity.
- Adjusted-vs-reported EPS gap: recurring "special" items (amortization, integration) mean the flattering ~$10.7 adjusted number sits ~$1 above ~$9.7 reported — quality-of-earnings caution.
- Valuation / de-rating: 24× trailing near the 52-week high leaves little margin for a volume or pricing disappointment.
- No expert edge / low conviction: Synthos has zero KB coverage on DGX; the Street is a Hold. This is a name we have no differentiated informational advantage on — a reason for humility, reflected in the Watch verdict.
12. Verdict, position sizing & monitoring
Watch. Quest Diagnostics is a well-run, genuinely defensive US lab duopolist with reliable ~$1.4B free cash flow, a covered 1.5% dividend, and steady high-single-digit revenue / ~11% EPS growth. But it is fully priced (24× trailing, at the 52-week high, on consensus), carries elevated 3.1× leverage from its acquisition model, earns only ordinary margins and ~8% ROIC, and has no expert coverage in the Synthos KB to give us an edge. The Street's own verdict is Hold, and our base fair value ($220) lands on consensus — the honest signal that there is no mispricing to exploit today.
- Sizing: if owned at all, a small ~1–2% defensive/income sleeve position — not a flagship, next-exponential holding. Better bought on a pullback toward the rising 50-DMA (~$197) than at the highs.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $215.72.
- Single biggest risk: reimbursement/PAMA pricing pressure compounding with 3.1× leverage on a debt-funded roll-up.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — DGX has no expert coverage in the Synthos knowledge base. No
claim_ids exist to cite, and none were fabricated. The verdict is explicitly fundamentals- and quant-driven, cross-checked against management's half-weighted guidance. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release filed 2026-04-21. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: DGX management guidance (raised FY26 revenue $11.78–11.90B, adjusted EPS $10.63–10.83) is management's own book, half-weighted by design; adjusted EPS excludes recurring integration/amortization items.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").